Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy

Autor: Daniel C. Cattran, Jürgen Floege, Rosanna Coppo

Publikováno v: Kidney International Reports, Vol 8, Iss 12, Pp 2515-2528 (2023)

The highly variable rate of decline in kidney function in patients with immunoglobulin A nephropathy (IgAN) provides a major clinical challenge. Predicting which patients will progress to kidney failure, and how quickly, is difficult. Multiple novel

Externí odkaz: https://doaj.org/article/bbfd81f9e1e94c739fa4f1788e9be0ad

Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses

Autor: Elissa G. Currie, Bryan Coburn, Elisa A. Porfilio, Ping Lam, Olga L. Rojas, Jan Novak, Stuart Yang, Raad B. Chowdhury, Lesley A. Ward, Pauline W. Wang, Khashayar Khaleghi, James An, Sarah Q. Crome, Michelle A. Hladunewich, Sean J. Barbour, Daniel C. Cattran, Rulan S. Parekh, Christoph Licht, Rohan John, Rupert Kaul, Kenneth Croitoru, Scott D. Gray-Owen, David S. Guttman, Jennifer L. Gommerman, Heather N. Reich

Publikováno v: JCI Insight, Vol 7, Iss 5 (2022)

IgA nephropathy (IgAN) is a leading cause of kidney failure, yet little is known about the immunopathogenesis of this disease. IgAN is characterized by deposition of IgA in the kidney glomeruli, but the source and stimulus for IgA production are not

Externí odkaz: https://doaj.org/article/594e642df71840fcba72985a2ef82850

The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis

Autor: Jingyuan Xie, Lili Liu, Nikol Mladkova, Yifu Li, Hong Ren, Weiming Wang, Zhao Cui, Li Lin, Xiaofan Hu, Xialian Yu, Jing Xu, Gang Liu, Yasar Caliskan, Carlo Sidore, Olivia Balderes, Raphael J. Rosen, Monica Bodria, Francesca Zanoni, Jun Y. Zhang, Priya Krithivasan, Karla Mehl, Maddalena Marasa, Atlas Khan, Fatih Ozay, Pietro A. Canetta, Andrew S. Bomback, Gerald B. Appel, Simone Sanna-Cherchi, Matthew G. Sampson, Laura H. Mariani, Agnieszka Perkowska-Ptasinska, Magdalena Durlik, Krzysztof Mucha, Barbara Moszczuk, Bartosz Foroncewicz, Leszek Pączek, Ireneusz Habura, Elisabet Ars, Jose Ballarin, Laila-Yasmin Mani, Bruno Vogt, Savas Ozturk, Abdülmecit Yildiz, Nurhan Seyahi, Hakki Arikan, Mehmet Koc, Taner Basturk, Gonca Karahan, Sebahat Usta Akgul, Mehmet Sukru Sever, Dan Zhang, Domenico Santoro, Mario Bonomini, Francesco Londrino, Loreto Gesualdo, Jana Reiterova, Vladimir Tesar, Claudia Izzi, Silvana Savoldi, Donatella Spotti, Carmelita Marcantoni, Piergiorgio Messa, Marco Galliani, Dario Roccatello, Simona Granata, Gianluigi Zaza, Francesca Lugani, GianMarco Ghiggeri, Isabella Pisani, Landino Allegri, Ben Sprangers, Jin-Ho Park, BeLong Cho, Yon Su Kim, Dong Ki Kim, Hitoshi Suzuki, Antonio Amoroso, Daniel C. Cattran, Fernando C. Fervenza, Antonello Pani, Patrick Hamilton, Shelly Harris, Sanjana Gupta, Chris Cheshire, Stephanie Dufek, Naomi Issler, Ruth J. Pepper, John Connolly, Stephen Powis, Detlef Bockenhauer, Horia C. Stanescu, Neil Ashman, Ruth J. F. Loos, Eimear E. Kenny, Matthias Wuttke, Kai-Uwe Eckardt, Anna Köttgen, Julia M. Hofstra, Marieke J. H. Coenen, Lambertus A. Kiemeney, Shreeram Akilesh, Matthias Kretzler, Lawrence H. Beck, Benedicte Stengel, Hanna Debiec, Pierre Ronco, Jack F. M. Wetzels, Magdalena Zoledziewska, Francesco Cucca, Iuliana Ionita-Laza, Hajeong Lee, Elion Hoxha, Rolf A. K. Stahl, Paul Brenchley, Francesco Scolari, Ming-hui Zhao, Ali G. Gharavi, Robert Kleta, Nan Chen, Krzysztof Kiryluk

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)

Membranous nephropathy (MN) is a rare autoimmune disease of podocyte-directed antibodies, such as anti-phospholipase A2 receptor. Here, the authors report a genome-wide association study for MN and identify two previously unreported loci encompassing

Externí odkaz: https://doaj.org/article/673c37d7cf9b414b91486e389bd81da8

Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Autor: Minnie M. Sarwal, Nicole Arceneaux, Jonathan Barratt, Mark D. Stegall, Christine B. Sethna, Debbie S. Gipson, Shadab Ali, Richard J.H. Smith, Matthew C. Pickering, Lindsey Fuller, Brad H. Rovin, Ashley Frazer-Abel, Carla M. Nester, Rasheed Gbadegesin, Fernando C. Fervenza, Gerald B. Appel, Samir V. Parikh, Daniel C. Cattran, Véronique Frémeaux-Bacchi, Cathie Spino, Sanjay Ram, Pierre Ronco, Laura Bailey-Wickins, Paolo Cravedi, Jonathan J. Hogan, Joshua M. Thurman, Laurence H. Beck, John D. Mahan, Marina Vivarelli, Isa Ashoor, Michelle N. Rheault, Elif Erkan, David L. Feldman, Richard J. Quigg, Richard A. Lafayette, Peter S. Heeger, Andrew S. Bomback, Moglie le Quintrec-Donnette, Michelle A. Hladunewich, Christoph Licht, Krzysztof Kiryluk, Howard Trachtman

Publikováno v: American Journal of Kidney Diseases. 79:570-581

Blocking the complement system as a therapeutic strategy has been proposed for numerous glomerular diseases but presents a myriad of questions and challenges, not the least of which is demonstrating efficacy and safety. In light of these potential is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a29f2aa65461cb54b2d38634cfceef16
https://doi.org/10.1053/j.ajkd.2021.07.025

Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis

Autor: Arenn, Jauhal, Heather N, Reich, Michelle, Hladunewich, Moumita, Barua, Bettina E, Hansen, David, Naimark, Stéphan, Troyanov, Daniel C, Cattran

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Although the clinical benefit of obtaining a remission in proteinuria in nephrotic patients with focal and segmental glomerulosclerosis (FSGS) is recognized, the long-term value of maintaining it and the impact of relapses on outcome are not well des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9deb6ae2fe1468c133a6c7b36750609b
https://pubmed.ncbi.nlm.nih.gov/35948275